Quick summary
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on pineal epithalamin that activates telomerase and stimulates melatonin production. It is not FDA-approved and is sold internationally as a research chemical.
Overview
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. It was discovered by Russian gerontologist Professor Vladimir Khavinson, who spent over 35 years researching peptide bioregulators. Epithalon is the most studied peptide in the field of aging, specifically for its ability to activate telomerase and extend telomere length.
Mechanism of action
Epithalon activates telomerase, the enzyme that adds telomeric repeats (TTAGGG) to the ends of chromosomes, counteracting the telomere shortening that occurs with each cell division and is associated with aging. It also stimulates melatonin production by the pineal gland, regulates the neuroendocrine system, and normalizes anterior pituitary function. Khavinson's research suggests it acts as a peptide bioregulator at the gene expression level.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| anti-aging / telomerase activation | subcutaneous | 5–10 mg | daily | Typical protocol: 5-10mg daily for 10-20 days, repeated every 4-6 months. Based on Khavinson's clinical protocols. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Khavinson's research spans 35+ years and over 100 publications. Key findings: telomerase activation in human somatic cells in vitro, increased telomere length, extended lifespan in animal models (mice: 13.3% increase). A 15-year human observational study on elderly patients showed reduced mortality (1.6-1.8x) in the epithalamin group. Pineal gland function restoration and melatonin normalization demonstrated in aged patients. Limitations: most human data is from Russian studies with limited Western peer review.[1][2][3][4][5][6]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Epithalon for synergistic effects.
Legal status
Not FDA-approved. Available as a research peptide. Epithalamin (the natural extract) is approved in Russia as a pharmaceutical. The synthetic version (Epithalon) is sold as a research chemical internationally.
Sourcing & access
Research compound
Epithalon is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural extract of the bovine pineal gland. It was developed by Russian gerontologist Vladimir Khavinson, who has studied pineal peptides for over 35 years. Epithalon is the primary synthetic compound from his research program and has been studied for telomerase activation, melatonin regulation, and longevity.
Epithalon activates telomerase, the enzyme responsible for adding TTAGGG repeats to chromosome ends, thereby maintaining telomere length and reducing replicative senescence in somatic cells. It also stimulates melatonin secretion from the pineal gland, normalizes pituitary function, and may modulate hypothalamic neuroendocrine signaling. These combined effects are proposed to slow the biological aging process.
Epithalon is not approved by the FDA or most international regulatory agencies as a drug for any indication. Epithalamin (the natural pineal extract) has been approved in Russia. The synthetic peptide epithalon is sold internationally as a research chemical without prescription. Its legal status for human use varies by country, and it is not classified as a controlled substance in the United States.
Research protocols derived from Khavinson's clinical work typically use 5 to 10 mg per day by subcutaneous or intramuscular injection. Cycle lengths are 10 to 20 consecutive days, repeated every 4 to 6 months. This cyclic protocol is designed to mimic the intermittent pineal peptide exposure observed in biological systems rather than continuous supplementation.
Animal studies using transgenic HER-2/neu mice showed a 13.3 percent increase in median lifespan with epithalamin treatment. A 15-year observational study in elderly humans by Khavinson et al. reported 1.6 to 1.8 times lower all-cause mortality in subjects receiving periodic epithalamin compared to controls. This human data is observational, not a randomized controlled trial, limiting its evidentiary weight.
Epithalon has a favorable safety profile in the published literature. The most commonly reported side effects are injection site discomfort and rare mild flu-like symptoms (fatigue, low-grade fever) during the first 1 to 2 days of a new cycle. Transient drowsiness has been reported, consistent with its melatonin-stimulating effects. No serious adverse events or organ toxicity have been documented in available studies.
Epithalon's plasma half-life is estimated at approximately 2 to 3 hours, though this figure is not precisely characterized in published pharmacokinetic studies. Its short half-life is consistent with other small tetrapeptides and supports the daily injection protocols used in Khavinson's research. The biological effects on gene expression and telomerase activity appear to persist beyond the peptide's plasma clearance.
Research references
- Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsPubMed
- Peptide Epitalon activates chromatin at the old agePubMed
- AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic MechanismPubMed
- Peptides of pineal gland and thymus prolong human lifePubMed
- Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising PropertiesPubMed
- Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly peoplePubMed